
ADMA Biologics Faces Class Action Over Alleged Securities Violations
Investors who held ADMA Biologics stock between August 9, 2024, and March 25, 2026, are being urged to join a class action lawsuit filed against the company. The litigation centers on allegations that ADMA misled the market regarding its financial health and internal business practices.























